Last reviewed · How we verify
NCT06948331: RAD
RADA16 for Aquablation Day Case
Phase 2 trial testing PuraStat in Hematuria in 25 participants. Not yet recruiting.
1 July 2026
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 25 |
| Start date | 1 April 2026 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PuraStat
Conditions studied
- Hematuria — all drugs for Hematuria →
- Benign Prostatic Hyperplasia — all drugs for Benign Prostatic Hyperplasia →
- Lower Urinary Tract Symptoms — all drugs for Lower Urinary Tract Symptoms →
Sponsor
NYU Langone Health — full company profile →
Who can join
Eligibility, male only, with Hematuria or Benign Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge. The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation. The secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06948331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematuria
Currently open trials in the same condition.
- NCT07037589 — Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? · recruiting
- NCT07395037 — A Study of Ward Admissions for Haematuria · recruiting
- NCT06026189 — Safely Reduce Cystoscopic Evaluations for Hematuria Patients · NA · recruiting
- NCT05620784 — Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP · Phase 3 · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06948331 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06948331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing